Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 2/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5314369 | 0.82 | CES2 (0.57) | CES2CES1ALDH1A1KDM4EMAPT | |
| SCHEMBL11286933 | 0.82 | MEN1 (0.46) | CSNK2A1HDAC7LMNATSHRMEN1 | |
| SCHEMBL18714113 | 0.80 | CSNK2A1 (0.41) | CPS1CSNK2A1LOXL2CES2CES1 | |
| SCHEMBL15539727 | 0.79 | MAP2K1 (0.39) | CES2CES1MAP2K2MAP2K1 | |
| SCHEMBL8348114 | 0.79 | TRPA1 (0.42) | CES2CES1LMNATSHRKMT2A | |
| SCHEMBL28754538 | 0.79 | CPS1 (0.54) | CPS1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL19121284 | 0.77 | CSNK2A1 (0.39) | CPS1CSNK2A1LOXL2CES2CES1 | |
| SCHEMBL15541210 | 0.77 | GAA (0.48) | CES2ALDH1A1KDM4EHPGDHTT | |
| SCHEMBL9726681 | 0.75 | CSNK2A1 (0.47) | CPS1CSNK2A1LOXL2CES2CES1 | |
| SCHEMBL4145212 | 0.74 | CES2 (0.54) | CES2CES1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2016-11-24 | — | — | US | disclosed |
| US-9439890-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-09-13 | — | — | US | disclosed |
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | Ichnos Sciences SA (CH) | 2015-10-08 | — | — | US | disclosed |
| US-9096545-B2 | Triazolone compounds as mPGES-1 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-08-04 | — | — | US | disclosed |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150283117-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGIS, PTGS1 | CPS1 3956/4885CSNK2A1 2630/4885LOXL2 1681/4885 |
| US-20160339000-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | CPS1 3344/4885CSNK2A1 1965/4885LOXL2 1599/4885 |
| US-20150087646-A1 | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | PTGES, PTGS1, PTGIS | CPS1 3344/4885CSNK2A1 1965/4885LOXL2 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.